Clovis Oncology (NASDAQ:CLVS) – Why Are Clovis Oncology Stocks Higher Today?


Clovis Oncology Inc CLVS Shares are trading higher on Monday after the company presented data showing that Rubraca as a first-line maintenance treatment improved progression-free survival in advanced ovarian cancer.

Clovis announced the results of a subgroup analysis of data from the randomized Phase 3 ATHENA monotherapy comparison trial over the weekend. Rubraca as first-line maintenance therapy improved progression-free survival compared to placebo in disease risk subgroups, including surgical outcomes, response to first-line chemotherapy, and additional analyzes in other subgroups.

“As demonstrated by the additional data presented at ESMO, the ATHENO-MONO analysis continues to reinforce the potential of Rubraca as a first-line maintenance treatment for women with advanced ovarian cancer” , said Patrick MahaffyPresident and CEO of Clovis Oncology.

Clovis is a biopharmaceutical company focused on the acquisition, development and commercialization of innovative anticancer agents in the United States, Europe and other international markets.

See also: Why InMed Pharmaceuticals stock is rising today

CLVS Price Action: Clovis has a 52-week high of $3.25 and a 52-week low of 58 cents.

The stock was up 13.9% at $1.30 at press time, according to BenzingaPro.

Photo: Tatyana from Pixabay.


Comments are closed.